Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of UT-MeV1 in Nectin-4 positive solid tumors
jRCT2033210698Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2022
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of UT-MeV1 in Nonhematologic neoplasms (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety. Started Sep 2022; status: active, not recruiting.
02
Drugs
UT-MeV1
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2033210698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033210698.